Immunic Regains Nasdaq Minimum Bid Price Compliance, Resolving Delisting Threat
Summary
Immunic, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, removing a significant delisting risk that was highlighted in its recent 10-K filing.
Key Events
-
Regained Nasdaq Compliance
Immunic, Inc. received notification from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement. This was achieved by maintaining a closing bid price of at least $1.00 per share for 20 consecutive business days, from February 27, 2026, to March 26, 2026.
-
Removes Delisting Threat
The compliance notification closes the matter, effectively removing the immediate threat of delisting from The Nasdaq Capital Market due to the minimum bid price deficiency.
-
Addresses Prior 10-K Concerns
This positive development directly addresses the 'ongoing Nasdaq compliance issues' and the potential need for a 'proposed reverse stock split' that were highlighted in the company's Annual Report on Form 10-K filed on February 26, 2026.
Analysis
This filing is important as Immunic, Inc. has officially regained compliance with Nasdaq's minimum bid price requirement. This resolves a significant compliance issue that was explicitly mentioned in the company's recent 10-K filing (2026-02-26) as a factor potentially requiring a reverse stock split. By maintaining a bid price above $1.00 for 20 consecutive business days, the company has removed an immediate delisting threat, providing stability regarding its exchange listing.
At the time of this filing, IMUX was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $144.8M. The 52-week trading range was $0.51 to $1.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.